Ofelia Baniandres-Rodriguez

46 Doctor Esquerdo St
Madrid, MD 28007, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Safety Profile of Systemic Therapy for the Management of Psoriasis in Patients With Diabetes Mellitus: Data From the BIOBADADERM Prospective Cohort.

Safety Profile of Systemic Therapy for the Management of Psoriasis in Patients With Diabetes Mellitus: Data From the BIOBADADERM Prospective Cohort.

Journal: Actas dermo-sifiliograficas

Published: December 31, 2025

Safety Profile of Systemic Therapy for the Management of Psoriasis in Patients With Diabetes Mellitus: Data From the BIOBADADERM Prospective Cohort.

Safety Profile of Systemic Therapy for the Management of Psoriasis in Patients With Diabetes Mellitus: Data From the BIOBADADERM Prospective Cohort.

Journal: Actas dermo-sifiliograficas

Published: December 31, 2025

Cardiovascular safety of systemic psoriasis treatments: A prospective cohort study in the BIOBADADERM registry.

Cardiovascular safety of systemic psoriasis treatments: A prospective cohort study in the BIOBADADERM registry.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: October 13, 2024

Risk of adverse events of psoriasis treatment with biologic agents and new small molecules-BIOBADADERM Registry.

Risk of adverse events of psoriasis treatment with biologic agents and new small molecules-BIOBADADERM Registry.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: September 21, 2024

Survival of Interleukin-17 and Interleukin-23 Inhibitors in Patients Previously Treated With a Tumor Necrosis Factor Inhibitor: Analysis of the Spanish Biobadaderm Registry.

Survival of Interleukin-17 and Interleukin-23 Inhibitors in Patients Previously Treated With a Tumor Necrosis Factor Inhibitor: Analysis of the Spanish Biobadaderm Registry.

Journal: Actas dermo-sifiliograficas

Published: May 15, 2024

Experience of patients with immune-mediated inflammatory diseases seen in a multidisciplinary integrated care unit

Experience of patients with immune-mediated inflammatory diseases seen in a multidisciplinary integrated care unit

Journal: Journal of healthcare quality research

Published: November 05, 2023

Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.

Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: July 03, 2023

Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry.

Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry.

Journal: The British journal of dermatology

Published: May 24, 2023

[Translated article] Family Planning Concerns Among Women With Psoriasis: A Descriptive, Cross-Sectional, Multicenter Study.

[Translated article] Family Planning Concerns Among Women With Psoriasis: A Descriptive, Cross-Sectional, Multicenter Study.

Journal: Actas dermo-sifiliograficas

Published: March 30, 2023

[Translated article] Elderly-Onset Generalized Pustular Psoriasis in the Elderly: A 5-Case Series.

[Translated article] Elderly-Onset Generalized Pustular Psoriasis in the Elderly: A 5-Case Series.

Journal: Actas dermo-sifiliograficas

Published: December 18, 2022

Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors.

Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors.

Journal: European journal of hospital pharmacy : science and practice

Published: October 25, 2022

Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients.

Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients.

Journal: Dermatologic therapy

Published: August 23, 2022

Showing 1-12 of 50

Last Updated: 09/26/2026